Bonkers Bargain: new platform offers loads of potential
This small medical imaging advanced analytics company delivering insights in neuroscience has loads of potential and continues to look cracking value at current levels. Our in-depth commentary here highlights its appeal in a sector which is predicted to grow significantly. The order book offers plenty of visibility and this fascinating business is certainly worth a close look. Encouraging results from a drug being developed for Alzheimers disease is positive, while an equity raise has strengthened the balance sheet. It's certainly not our usual type of Bonkers Bargain, but exciting nonetheless!
IXICO (LON:IXI) is an Artificial Intelligence (‘AI’) data analytics company delivering intelligent insights in neuroscience. Its purpose is to advance medicine and human health in neuroscience by converting raw clinical trial data into clinically meaningful information. Through the deployment of novel Artificial Intelligence (‘AI’) algorithms, IXICO analyses and interprets brain scans and wearable biosensor data to enable better trial design, patient selection and ultimately better clinical outcomes across all phases of clinical evaluation. The Group is a trusted partner to the global pharmaceutical industry, developing new therapies for neurological conditions with unmet clinical needs, including Alzheimer’s, Parkinson’s and Huntington’s diseases.Background…